Bevacizumab biosimilar (Synermore Biologics)

贝伐珠单抗生物类似药（兴盟生物科技）

Report date: 2024/03/01 17:19:57

Base Information

Drug NameBevacizumab biosimilar (Synermore Biologics)
Drug Alias Name贝伐人源化单抗生物仿制药（兴盟生物科技）贝伐赛珠单抗生物仿制药（兴盟生物科技）贝伐株单抗生物仿制药（兴盟生物科技）贝伐单抗生物仿制药（兴盟生物科技）SYN-050
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (IND)
Highest Status in ChinaPending
Originator CompaniesSynermore Biologics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSynermore Biologics (Suzhou) Co LtdLonn Ryonn Pharma Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01XC07
Related LinksN/A